Cleerly LABS vs AVIEW
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary objective is a deep, AI-powered analysis of coronary CT angiography (CCTA) to precisely quantify and characterize atherosclerosis and stenosis. This tool is ideal for clinicians focused on personalized heart disease management, including tracking disease progression and assessing ischemia, to proactively address cardiovascular risk.
View Cleerly LABS →Choose AVIEW if…
Choose AVIEW if you require a versatile AI platform for comprehensive thoracic CT scan analysis, encompassing lung cancer screening, COPD assessment, and coronary artery calcium (CAC) scoring. This solution is best suited for radiology departments seeking to streamline workflows and enhance diagnostic precision across multiple pulmonary and cardiac conditions from standard CT scans.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | AVIEW |
|---|---|---|
| Pricing | Varies | Subscription; one-off payment |
| Deployment | Cloud, On-premise | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWAVIEW offers greater deployment flexibility, including cloud, hybrid, and on-premise options, which can cater to diverse IT infrastructures and user preferences. Its explicit mention of workflow automation and integration with existing radiology systems (PACS/RIS/CIS) also suggests a strong focus on seamless user experience within clinical settings.
Clinical Value
Cleerly LABSCleerly LABS provides a highly specialized and deep analysis of CCTA for comprehensive coronary plaque characterization and ischemia detection, which is critical for personalized heart disease management and prevention. Its focus on 'creating a new standard of care to eliminate heart attacks' highlights a potentially transformative clinical impact in its specific cardiovascular domain.
Pricing & Value
AVIEWAVIEW offers more flexible pricing models, including subscription and one-off payment options based on installations or users, which can provide greater predictability and cost-effectiveness for enterprise deployments. Cleerly's per-analysis model, while transparent, may lead to higher cumulative costs for high-volume centers and highlights potential out-of-pocket expenses for patients.
Enterprise Readiness
AVIEWAVIEW demonstrates superior enterprise readiness due to its extensive deployment flexibility, supporting cloud, hybrid, on-premise, and virtualized environments. This adaptability allows it to integrate more seamlessly into diverse and complex hospital IT infrastructures and security requirements compared to Cleerly's primarily cloud-based approach with an on-site proxy.
Innovation
Cleerly LABSCleerly LABS exhibits a higher degree of innovation by focusing on a comprehensive and detailed characterization of coronary plaque beyond traditional stenosis, aiming to redefine heart attack prevention. While AVIEW offers a broad and valuable suite of AI tools, Cleerly's specialized depth in advanced CCTA analysis represents a more novel approach in its specific domain.
Support & Docs
TieNeither the provided structured facts nor readily available public information from web searches offer sufficient details regarding the specific support channels, service level agreements, or documentation quality for either Cleerly LABS or AVIEW. Both companies provide contact forms for support, but detailed comparative information is lacking.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | AVIEW |
|---|---|---|
| Primary Application Area | Comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows. |
| Key Cardiovascular Analysis | AI-powered CCTA image analysis, Comprehensive coronary plaque assessment (volume, type), Stenosis detection and quantification, Ischemia detection (with Cleerly ISCHEMIA module), Personalized heart disease risk assessment. | Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification), Automated segmentation of coronary arteries. |
| Key Pulmonary Analysis | Not specified | AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score), Emphysema quantification and low attenuation area (LAA) analysis, Automated segmentation of lung lobes, airways, vessels, Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture). |
| 3D Visualization | 3D visualization of coronary arteries | 3D visualizations |
| Integration Capabilities | Integration with PACS, RIS, EHR via Cleerly Proxy | Workflow automation and integration with PACS/RIS/CIS |
| Disease Progression/Follow-up | Tracking disease progression over time | Follow-up registration and nodule matching for serial CT scans |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and AVIEW.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or AVIEW
Backers
Who funded each tool's parent company.